company background image
GLS logo

Glenmark Life Sciences NSEI:GLS Stock Report

Last Price

₹853.35

Market Cap

₹105.1b

7D

-1.7%

1Y

41.9%

Updated

14 Jun, 2024

Data

Company Financials +

Glenmark Life Sciences Limited

NSEI:GLS Stock Report

Market Cap: ₹105.1b

GLS Stock Overview

Engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.

GLS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance3/6
Financial Health6/6
Dividends3/6

Glenmark Life Sciences Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Glenmark Life Sciences
Historical stock prices
Current Share Price₹853.35
52 Week High₹906.00
52 Week Low₹555.85
Beta0.13
1 Month Change3.91%
3 Month Change15.42%
1 Year Change41.87%
3 Year Changen/a
5 Year Changen/a
Change since IPO14.01%

Recent News & Updates

Recent updates

Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

Aug 07
Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

May 10
A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Feb 15
Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Shareholder Returns

GLSIN PharmaceuticalsIN Market
7D-1.7%2.8%3.7%
1Y41.9%54.0%44.7%

Return vs Industry: GLS underperformed the Indian Pharmaceuticals industry which returned 54% over the past year.

Return vs Market: GLS underperformed the Indian Market which returned 44.7% over the past year.

Price Volatility

Is GLS's price volatile compared to industry and market?
GLS volatility
GLS Average Weekly Movement4.8%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.6%
10% most volatile stocks in IN Market9.6%
10% least volatile stocks in IN Market4.3%

Stable Share Price: GLS has not had significant price volatility in the past 3 months.

Volatility Over Time: GLS's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20111,824Yasir Rawjeewww.glenmarklifesciences.com

Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies.

Glenmark Life Sciences Limited Fundamentals Summary

How do Glenmark Life Sciences's earnings and revenue compare to its market cap?
GLS fundamental statistics
Market cap₹105.14b
Earnings (TTM)₹4.71b
Revenue (TTM)₹22.83b

22.2x

P/E Ratio

4.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GLS income statement (TTM)
Revenue₹22.83b
Cost of Revenue₹10.02b
Gross Profit₹12.81b
Other Expenses₹8.10b
Earnings₹4.71b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)38.43
Gross Margin56.11%
Net Profit Margin20.62%
Debt/Equity Ratio0%

How did GLS perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

59%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.